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We measured the perception of competition in the market for essential and orphan drugs. 
The inflation rate for original products was 0.002 annually, whereas that for generic 
drugs was 0.005. The province of Panama, containing 46.5 % of private pharmacies, has 
the lowest index in the perception of competition; 18 % of the respondents to the out-of-
pocket expenditure survey did not have drugs available, and 55 % could not afford them. 
The Gini coefficients were 0.40 (2014) and 0.76 (2017). The increase in prices, the relative 
independence of retailers to establish prices, and low access to social/private insurance 
increase the out-of-pocket expenses.
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Medicamentos esenciales y huérfanos en Panamá:  
percepción de la competencia e implicaciones  
de la política de precios
Resumen
Medimos la percepción de competencia en el mercado de medicamentos esenciales y 
huérfanos. La tasa de inflación de los productos originales fue de 0.002 anuales, mientras 
que la de los medicamentos genéricos fue de 0.005. La provincia de Panamá, que contiene el 
46.5 % de las farmacias privadas, tiene el índice más bajo en la percepción de competencia. 
El 18 % de los encuestados en la encuesta de gastos de bolsillo no tenía medicamentos 
disponibles y el 55 % no podía pagarlos. Los coeficientes de Gini fueron 0.40 (2014) y 0.76 
(2017). El aumento de los precios, la relativa independencia de los minoristas para establ-
ecer los precios y el bajo acceso al seguro social/privado aumentan los gastos de bolsillo.
Palabras clave: competencia económica, política de medicamentos genéricos, medicamentos 
huérfanos, farmacia, equivalencia terapéutica.
Clasificación jel: H5 National Government Expenditures and Related Policies: H51, H53, H55.
Medicamentos essenciais e órfãos no Panamá: percepção  
da concorrência e implicações da política de preços
Resumo
Medimos a percepção de concorrência no mercado de medicamentos essenciais e órfãos. A 
taxa de inflação dos produtos originais foi de 0.002 anuais, enquanto a dos medicamentos 
genéricos foi de 0.005. A província do Panamá, que contém o 46.5 % das farmácias privadas, 
tem o índice mais baixo na percepção de concorrência. O 18 % dos inqueridos na enquete 
de despesas de bolso não tinha medicamentos disponíveis e o 55 % não podia pagá-los. 
Os coeficientes de Gini foram 0.40 (2014) e 0.76 (2017). O aumento dos preços, a relativa 
independência dos retalhistas para estabelecer os preços e o baixo acesso à segurança 
social / privada aumentam as despesas de bolso.
Palavras-chave: concorrência económica, política de medicamentos genéricos, medicamentos 
órfãos, farmácia, equivalência terapêutica.
Classificação jel: H5 National Government Expenditures and Related Policies: H51, H53, H55.
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Introduction
The upward price increase in both generic and original products after the 
release of cap prices in 2004, whereby the market was left to free supply and 
demand, has left reasonable doubts as to the effectiveness of this measure. 
So the importance of addressing this problem goes beyond the structural 
characteristics of the Panamanian market, making it necessary to investigate 
aspects related to the conduct of economic operators along the marketing 
channel, as well as how the perceived competition environment, in addition 
to the degree of independent pricing in the retail segment.
Concerning orphan drugs sold in hospitals in general, there is no clear 
idea of whether there are policies regarding the management of lists in 
pharmacies, distributor companies, and manufacturers. These drugs are 
essential for the treatment of rare diseases. This aspect has been a great 
conflict between patients and the public health system in Panama, and even 
in other countries of the Americas, regarding their supply.
Given these facts, it is necessary to carry out a comprehensive analysis of 
public policies, regarding the functioning of the drug market, in the context 
of social inefficiency. Panama is one of the countries of the Americas with one 
of the worst distributions, drug supply problems, and access to out-of-pocket 
spending in the private sector, which is a complex problem to consider in the 
forthcoming reform of the public health and social security system, under 
a model common to that of many countries in the Americas, such as Chile, 
which makes it necessary to open up the debate on national drug policy in 
the current circumstances.
While there are publications on the drug market in different parts of the 
world, they do not generally address certain particular aspects of countries 
that, as in the case of Panama, are importers of medicines, and small econo-
mies such as those of Central America, which share common realities in the 
face of this problem. In general, many countries in the Americas continue 
to face health services’ inequality in the health sector; alternatives to this 
problem have been sought, focused on comprehensive reforms supported 
by international organisations such as the World Bank, the World Health 
Organization (who) or Pan American Health Organization (paho) (Vargas 
et al., 2008).
Drug marketing is complicated due to its implications for social equity in 
health and its strong influence on the budgets of public health systems (Abdel 
Rida & Ibrahim, 2018; Martín-Conde, Tévar Alfonso, & García García, 2011; 
Gorgas, 2014). Since 2004, Panama has had a policy of prices established for 
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free supply and demand in the medicines market, in which it is expected that 
generic medicines will generate greater price competition than innovative 
medicines (Gorgas, 2014).
The use of this competitive scheme continues to generate debate, regard-
ing its efficacy for prices and medications’ access, particularly for those 
living in low-income regions, in which the approaches of market regulation 
and competition policy are contrasted under imperfect market structures 
(Lobo, 2014; Oliva, 2015). Furthermore, the current situation with orphan 
drugs is challeging; the low incidence of rare diseases results in very high 
prices in the private market, increasing the budget pressures on the public 
health systems. In general, orphan drugs are for hospital use, they acquire 
them directly from the distributors for their internal use, and few of these 
medications are sold directly to the public.
Panama has not escaped from this reality, and in the last three decades, 
the country has followed a scheme that has shifted from regulated prices to, in 
2004, prices set for free supply and demand. In 1969, a system of price regula-
tion, by means of the Decree No. 60, was launched, and it ended with the Law 
29 of 1996 (repealed by Law 45 of 2007), moving to a system of regulation by 
exception when merited by the specific case (Asamblea Nacional de Panamá, 
1969, 1996, 2007). Law 1 of 2001 established the previous and subsequent 
control of medicines as well as the bioequivalence, surveillance, and safety 
of medicines (Ley 1 de Medicamentos, 2001). Its article 102 established a price 
ceiling system for two years, leaving only the obligation of communicating 
increases by distributors as well as manufacturers, this mechanism ended 
in 2004, when Panama moved to a system of prices with free supply and 
demand. However, the main problem in the marketing of medicines to both 
the public and private sectors is exclusive distribution agreements between 
manufacturing laboratories and authorized distributors that do not allow 
the use of the parallel import mechanism established in Law 1, which would 
provide an alternative for import at lower prices. Meanwhile, the free trade 
agreements of medicines, especially those with developed countries, have 
been limited to the protection of intellectual property without technology 
transfer, which is an important issue to raise in most developing countries 
(Gamba, 2017).
This debate is highlighted by the escalating prices in recent years, which 
has had economic and social impacts on public and out-of-pocket expenditures 
on health (Herrera-Ballesteros, Castro & Gómez, 2018). In Panama, little is 
known about the functioning and organization of the medicine market and 
the competitive environment. Panama is characterized as an importer of most 
Víctor Herrera, Ilais Moreno, Eric Conte, Cecilio Hall, Beatriz Gómez
Revista de Economía del Rosario. Vol. 23. No. 2. Julio-Diciembre 2020. 1-20
5
medications and currently has two complex public systems for purchase, 
the Ministry of Health and the Panamanian Social Security Institution, 
that act separately. Nevertheless, the private sector establishes the prices. 
At the time of the study, there were nine manufacturing plants in Panama 
producing generic medicines at a low scale. Overall, Panama imports most 
of its medicines and is dominated by the distribution segment.
As shown in a study of 2011 conducted by Diego Petrecolla, Panama had a 
moderate degree of concentration, based on a Herfindahl-Hirschmann index 
of 932 for the five largest distributors and a C4 index of 56 % for the market 
share of the four main distributors. In accordance with the Panamanian 
guidelines for the analysis of vertical behaviours, a C4 index equal to or 
above 60 is considered a relevant collective market power, and, in this case, 
we can conceive it likely to capture an oligopoly structure in addition to al-
lowing control of prices. Examining other countries of Central America, the 
C4 index is 85 % in Costa Rica and 67 % in Nicaragua (Resolución A-30, 2009; 
Petrecolla, 2011; Shy, 1995). The retail segment for drugs consists of a large 
chain of pharmacies (N = 152), a small chain of pharmacies (N = 107), and 
community pharmacies or independent pharmacies (N = 439) (Ministerio de 
Salud, 2016). There are drugs for hospital use and those sold in the commu-
nity. Overall, the private market sales the drugs, and patients can purchase 
medicines in community pharmacies and hospital pharmacies. Distributors 
do not have pharmacies because vertical integration is prohibited in Panama. 
Nevertheless, there are pharmacy chains, some of which belong to the main 
supermarket chains in the country and have greater market control over 
independent pharmacies.
We aim to measure the perception of competition and the population’s 
access in the market to essential and orphan drugs in Panama under the 
current context of a pricing policy based on free competition. The data were 
obtained from three surveys: the market for essential medicines and or-
phans to collect perceptions, of 8.5 % (N = 59) from private pharmacies, 12 % 
(N = 17) of distributors, and nine existing laboratories; the 2014 and 2017 
Out-of-Pocket Essential Drug Surveys (N = 2721), and, finally, the Basic Drug 
Basket Database (cabamed N = 50 Private Pharmacies). The monthly price 
increase was calculated by linear regression. The competitive perception 
index was calculated using factor analysis, and the Gini coefficients were 
estimated for 2014 and 2017.
The main findings of this research include that the average annual price 
increase for original products was 2.4 %, and for generics, 6 %. In general, 
economic operators (laboratories, distributors, and retailers) agree that the 
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overall price increase was 5 %, and the principal cause was the increment in 
the price of the raw material. For distributors and laboratories, they generally 
do not have lists of orphan drugs as well as in pharmacies, so they still have no 
clear idea of the market situation for these medicines; 85 % of retailers, 64.7 % 
of distributors, and 55.5 % of laboratories consider the market competitive.
However, in the province of Panama, despite having 46.5 % of private 
pharmacies, the lowest perception rate of competition was obtained with 1.7971, 
with the overall index being 22 751. Concerning out-of-pocket expenditure 
on medicines, by 2017, 55 % of respondents reported not having sufficient 
resources to buy their medicines, while the Gini ratio rose from 0.40 to 0.76 
between 2014 and 2017 compared to that survey. These results make clear the 
problem of access to medicines and highlight the need to revise the pricing 
policy in addition to the rest of the regulations in this area.
This analysis has been organised into four sections, namely: materials 
and methods that address sources of information and statistical analysis; 
the results, which describe the main findings; the discussion, in which the 
results are contrasted with the most recent scientific evidence, and, finally, the 
conclusions, which put the results in context against the current environment.
Materials and Methods
Given the integrity of the proposed analysis, we combined the elements of 
competition policy such as the analysis of the structure, conduct, and per-
formance of economic operators; the evolution of prices, and the condition of 
population’s access to out-of-pocket expenditure to construct the perception 
of competition rate based on the criteria affecting price determination, the 
construction of price indices of generic and original or brand-branded medi-
cines, in addition to the Gini coefficients, with the 2014 and 2017 out-of-pocket 
surveys to analyse how the social gap has evolved, among other aspects.
We utilised data from three sources. The survey of the market of essential 
and orphan drugs was performed in the capitals of Panama’s ten provinces 
in 2016 (Ministerio de Salud, 2016). Out of the 698 private pharmacies exist-
ing in the country in 2016, 59 private pharmacies were randomly chosen at 
the national level. A survey was performed in each establishment by direct 
interview. A total of 140 distributors were registered in the country, and of 
those, 17 were chosen by simple random sampling selected in consensus with 
a panel of experts considering the principal distributors and to the widest 
medicines marketed variety.
Regarding the laboratories, the existing nine were selected, of which five 
are national. The survey was sent to the laboratories via email. The same 
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survey was administered to the pharmacies, the laboratories, and the distribu-
tors. The questionnaire was composed of 21 questions and included three 
variables: 1) the criteria to determine prices —for instance, does the price 
truly correspond to the product? Is the price established independently? Is the 
price suggested by the distributor, the manufacturer, or their headquarters? 
Is the price fixed according to the environment’s competitiveness?—; 2) the 
characteristics of the business —e.g., the company’s years of operation, the 
number of employees, incentive policies for sales or handling of orphan 
products—, and 3) the perception of competition —e.g., trends for prices in 
the last six months, the percentage increase in perceived competition in the 
market rated as competitive, very competitive, or uncompetitive—.
The second source of information is the survey of out-of-pocket expen-
ditures performed in 2014 and 2017. Briefly, the aim of the survey was to 
measure access to and availability of medicines and their rational use. The 
study population was composed of 2 721 individuals aged 18 years or more 
who were the head of the family randomly selected from urban, rural, and 
indigenous areas and distributed across six districts: Panama and San Miguelito 
(province of Panama), Colon (Colon Province), David (Chiriquí Province) and 
the indigenous areas of Madungandí and Besikó (Gorgas, 2014; 2017). This 
study was conducted by the Gorgas Memorial Institute for Health Studies 
and the Ministry of Health.
The third source of information is data from the monthly price index of 
essential drugs, derived from the essential drugs list —cabamed— (Resolución 
A-30). Cabamed was elaborated using 40 generic products and their corre-
sponding originals. The survey was performed in the District of Panama and 
included a total of 50 private pharmacies. This survey was carried out by the 
Authority of Consumer Protection and Defence of Competition (Autoridad 
de Protección al Consumidor y Defensa de la Competencia, 2015-2019).
Statistical Analysis
Three indicators were developed for the analysis. The first indicator was the 
average inflation rate from the monthly price index of the Cabamed, calcu-
lated using the Laspeyres formula (Gujarati, Guerrero, & Medina, 2004). The 
time frame analysed was from October 2014 to October 2015. It is a weighted 
index considering August 2013 as the base month and calculated for both 
the original reference (innovators) products and generic products (See equa-
tion 1). This indicator allows us to observe the recent price behaviour of the 
medicines and contextualize the perception of competition.
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P0i = Average price during the base period of product “i”.
Pni = Current average price of product “i”
Q0i = Quantity of the base period used for product “i”, depending on the 
type of treatment.
The inflation rate was estimated with a semi-logarithmic function, as 
shown in equation 2.
lnipm = ∝ + βt + u (2)
lnipm is the natural logarithm of the price index of medicines, t is the linear 
trend of the time series of real numbers, ranked sequentially from 1 to the 
nth observation (n = 13), and, finally, u is the stochastic error term (Gujarati, 
2009). Mathematically, it can be demonstrated that the derivative of lnipm 












The second indicator is the index of perception of competition in private 
pharmacies. As the data obtained from the laboratories and distributors 
encompassed a small sample size, the indicator could not be estimated due 
to the small sample, particularly the Keyser-Meyer-Olkin.
Therefore, to complement our statistical analysis, we performed a de-
scriptive analysis. Thus, we performed a factor analysis of the principal 
components with a polychoric correlations matrix (Mangin & Varela-Mallou, 
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1991). The variables used were “Perception of competition in the market” 
categorized as 1) very competitive, 2) new strategies, 3) uncompetitive, and 
4) bureaucratic bundle; “Price suggested by the Distributor” categorized as 
1) yes, 2) no, and 3) do not know; “Percentage rise in prices” categorized as 
1) up to 5 %, 2) between 6 % and 10 %, 3) between 11 % and 20 %, and 4) more 
than 21 %, and “Criteria for establishing the price” categorized as 1) considers 
the competition, 2) is the price that corresponds to the product, and 3) both.
Because we have politomic variables, a polychoric correlation matrix was 
first constructed, and then a principal component analysis was performed 
with two factors at the maximum. The first principal component was utilized. 
We estimated the index for every pharmacy by means of linear regression 
models and obtained a national and per province average indicator. Because 
factor 1 is a latent variable, we named it “perception of competition in the 
segment index retail” (pcsir). The analysis of the pcsir will be supplemented 
with the results of the surveys of distributors and laboratories.
The third indicator is the Gini coefficient, which is calculated based 
on the individual incomes of participants in the survey of out-of-pocket 
expenditures in 2014 and 2017. This indicator estimates the social gap and, 
complemented by the Lorenz curve, will contextualize social inequality in 
relation to economic access to the purchase of medicines under the current 
free competition system (Sen, Foster, & Galindo, 2001).
All calculations were performed with the software Stata 14.0 (StataCorp LP).
Results
Price Index Based on Reference and Generic Drugs 
in the Districts of Panama and San Miguelito
The beta coefficient for the original products was 0.002 (t x 4.906, p < 0.05), 
with an average monthly increase per month of 0.2 % or 2.4 % per year. For 
generic products, the beta coefficient was 0.005 (t x 7.904, p < 0.05), which 
represents a monthly increase rate of 0.5 % or 6.0 % per year. Although ge-
neric products are relatively less expensive compared to the reference, they 
experienced a rapid increase based on changing trends in August 2015, as 
shown in figure 1 (Autoridad de Protección al Consumidor y Defensa de la 
Competencia, 2015-2019).
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Figure 1. Drug Price Index by Type of Treatment for Reference and Generic 
Products in the Districts of Panama and San Miguelito. August 2013 = 100.0
Index of Perception of Competitiveness in Pharmacies
According to the survey of the market of drugs, 85 % of the pharmacies re-
sponded that the market is very competitive, and 41 % perceived that prices 
had risen between 5 % and 36 % in the last six months. Of these establishments, 
90 % perceived that prices had increased. The most frequent reason used 
to explain these increases was the rise in the cost of raw material —42 %— 
(Ministerio de Salud, 2016). Considering the criteria for establishing prices, 
only 20 % mentioned that the price is set based on prices at the surrounding 
pharmacies, and only 5 % said having a list of orphan drugs (Ministerio de 
Salud, 2016).
In relation to distributors, 11 of the 17 stated that the market is very 
competitive, 12 that prices were on the rise, seven that prices were rising 
by 5 %, and another 7 observed an increase from 6 % to 11 %. A total of 16 
of the distributors mentioned that the cause was the cost of the raw mate-
rial. However, 6 of the 17 stated that they had received recommendations 
to increase the price from the laboratories, and 15 of 17 expressed that the 
laboratories required them to respect the suggested price. Finally, only 4 of 
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the 17 distributors described having a policy for managing orphan medicinal 
products (Ministerio de Salud, 2016).
With respect to the laboratories, all stated that the market was very com-
petitive, and seven noted that prices had increased by 5 %. Similarly, eight 
stated that the reason for the increase was incremental cost increases in the 
raw material, and one explained that the increment was price inflation. Four 
of the nine laboratories mentioned that they instructed the distributors to 
raise prices, and only two described having the policy to manage orphan 
drugs (Ministerio de Salud, 2016). It is obvious that the price increases are 
aligned throughout the marketing channel.
The calculations for the index of perception of competitiveness in phar-
macies are presented in table 1. The reason for constructing a perception 
index was not to measure the degree of competition from a structural point 
of view, given that Diego Petrecolla’s study of 2010 is already available and 
that market structures rarely change in Panama, and it is a small market and 
an importer par excellence. In contrast, the index was constructed to measure 
the perception of the competitive environment and its possible relationship 
with the pricing decisions in the retail segment, in the sense of whether or 
not they truly have the freedom to establish prices, given that they represent 
the last link of the marketing chain and come into direct contact with the 
consumer. The variables with higher scores were perception of competition 
in the market (0.58357) and the criteria to establish the price (0.57659). The 
coefficient of Keyser-Meyer-Olkin global of 0.5044 is still within the minimum 
range of independence among factors (Ministerio de Salud, 2016).
Table 1. Score coefficients extracted by the regression 
method with varimax rotation
Variables Factor 1 Keyser-Meyer Olkin
Perception of competition in the market 0.58357 0.5039
Price suggested or not by the distributor 0.08986 0.5113
Percentage of increases in prices 0.10325 0.4915
Criteria to establish the price 0.57659 0.5069
General 0.5044
Figure 2 shows a graphical representation of the index estimates. The 
national average (total) was 2.2751, and we classify provinces according to a 
higher or lower perception of competition compared to the national average. 
The provinces with a more rural setting, such as Bocas del Toro, Darién, 
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Herrera, and Los Santos, had a higher perception of competition compared to 
the remaining provinces with a more urban environment, especially Panama, 
which held 46.5 % of all establishments (Ministerio de Salud, 2016).
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Figure 2. Index of Perception of Competition in Essential Medicines in Private 
Pharmacies by Province
Social Gap and Gini Coefficient
As shown in figure 3, the social gap has widened, as reflected in the Lorenz 
curves for 2014 and 2017. The Gini coefficient increased from 0.50 to 0.76 
(Gorgas, 2014; 2017). Notably, according to the World Bank, the Gini coef-
ficient was 0.51 in 2015 in Panama, suggesting that much of the population 
was excluded regarding access to medicines (Banco Mundial, 2014).
According to the results of both surveys, the annual average out-of-pocket 
expenditure was usd 86.25 in 2014 and usd 159.34 in 2017. In that same year, 
46 % of the participants did not have social security, and 89 % did not have 
private insurance (Gorgas, 2017). According to the data from the National 
Institute of Statistics and Census (inec) of Panama, informal employment 
in the country was 40.2 % in 2016, while it was 77.9 % in the Ngäbe-Buglé, an 
indigenous area (Censo, 2016).
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Figure 3. Social Gap in the Distribution of Income. Surveys of Out-of-Pocket 
Expenses in Medications 2014 and 2017
In 2017, 18 % of the study participants mentioned that drugs were not avail-
able, whereas, in 2014, it was 16.5 %. In 2017, 28% bought medicines without a 
prescription, while in 2014, it was 21 %. In that same year, 17 % said they had 
to borrow to buy their drugs, while that number in 2014 was 15 %. Finally, 
in 2017, 55 % stated that drug prices were not affordable (Gorgas, 2014; 2017).
Discussion
These results make it clear that the decisions regarding the retail prices are 
influenced by the laboratories, manufacturers, and distributors. Therefore, 
the perception that the market is very competitive is contradictory in light of 
these results. This finding raises questions about the expected effect of the 
current pricing policy based on free supply and demand. However, despite 
studies of interchangeability between innovative and generic products, some 
mechanisms of Law 1 have not been applied, such as parallel imports. This 
might be due to agreements regarding commercial exclusivity and the pricing 
policies of economic agents (Caja de Seguro Social, 2012).
We would expect that where there is a higher density of establishments, 
there will be a stronger perception of competition. In principle, the “perception 
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of competition” variable is neutralized by the variable “criteria to establish 
the price”, given that their scores are equivalent, making clear that retailers 
have little real independence to establish prices given the influence of chain 
pharmacies due to the oligopolistic structure of the latter, in that most are 
integrated into five major supermarket chains as well as into the segment 
of distributors and laboratories. This situation has had a negative impact on 
consumers, who have few options regarding prices. It also has generated 
access problems, particularly because Panama is among the countries in 
the Americas with the much unequal income distribution, as the Gini coef-
ficient showed, which exacerbates the inequity with respect to out-of-pocket 
expenses. The results make clear the high social vulnerability with regard to 
the precarious nature of the labour market, which may lead many individuals 
to incur a social risk of catastrophic expenses, in addition to the distributive 
inequality demonstrated by the Gini coefficient.
Our findings suggest that despite a system of free competition in prices, 
the upward trend in prices contradicts the perceptions that the market is 
very competitive in Panama. Moreover, our results suggest that there are 
limitations in access to the consumer segment and increases in prices in 
recent years, as reflected in the price index of medicines with cabamed data. 
Although, the market works under free competition in price, generic and 
innovative products have shown a trend of increased prices.
Regulation opposing competition policies sparks a controversial debate, 
particularly within the particularities of each country. Spain, for instance, has 
a much more strict regulatory policy compared to other European countries, 
and it proposes to encourage competition by lowering the prices of generic 
products, with funding and reimbursement schemes that require competitive 
bidding (Puig-Junoy, 2010). Spain aims to remove barriers to entry once the 
patent rights are ended; in the case of developing countries, these barriers 
become real obstacles to competition.
Even when 64 % of the pharmacies receive a bonus for minimum pur-
chases of products, there is no evidence that such benefits are transferred 
to consumers, especially for generic products. Less well known is the situ-
ation of orphan drugs, whose use is restricted primarily to hospitals and in 
many cases requires subsidy and risk-sharing policies that are cost-effective 
(Drummond et al., 2007; Owen et al. 2008).
However, in some countries of the Americas region, such as in Colombia, 
the efficiency of the pharmaceutical sector is being refocused based on the 
design of the quality of the processes, which results in the benefit of competi-
tiveness and reduces regulatory costs (García Aponte, Vallejo Díaz, & Mora 
Huertas, 2015). However, in a study for Peru, it is concluded that instead of 
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establishing price controls, what should be promoted is more competition 
between generic and brand name drugs, so that the gap between both types 
is closed more of products, given the fact that there were no clear trends 
between international and local prices (Miranda, 2006).
In Panama, law 28 of 2014 protects individuals with rare diseases, defined 
as those whose prevalence is fewer than one person per every 2000. Due to 
the low prevalence, the cost of care can become excessive in many cases, as 
observed in European countries (Asamblea Nacional de Panamá, 2014; Picavet 
et al., 2011). One could argue that this type of medication should not follow 
the same general pricing schemes as other pharmaceuticals, especially in 
developing countries facing environments of imperfect competition (Simoens, 
2011). This situation highlights the relationship between access to medicines 
and health equity. Policy interventions are needed, and price regulation 
should not be ruled out, generic products being the tip of the spear for this 
type of scheme (Ortún, 2008). Although our findings cannot demonstrate 
the performance of a practice that restricts competition, it is also not clear 
to what extent retailers are independent to establish their prices, especially 
in independent pharmacies.
Competition in prices in the segment retail is challenging. The presence 
of pharmacies within large chains, directly or indirectly, has an impact on 
the determination of prices at independent pharmacies, which depend on 
distributor provisioning systems. Panama is mainly an import country that 
established its national drug policy in 2009 to promote generic drugs and 
essential quality medicines under the system of free competition; however, 
the results of this policy are still controversial (A. N. d. l. R. d. Panamá, 2009; 
Gorgas, 2014; Ministerio de Salud, 2016; Gorgas, 2017). Similarly, its Law 1 of 
2001 allows parallel import but has been affected by contracts of exclusivity 
and challenge from some European countries, given their almost impercep-
tible impact on prices in some products, such as Simvastatin (Costa-Font & 
Kanavos, 2007; Ley 1 de Medicamentos, 2001). In Panama, national laboratories 
do not play a role in fixing prices because they have a reduced market share 
and produce generic products only, while distributors control the market and 
have exclusive relationships with regard to foreign laboratories that hold the 
patents on innovative products.
Although between December 2014 and July 2015, the trend in the price 
index of generic drugs was decreasing, from August 2015, there was a cyclic 
trend upward for the original reference drugs. The increase in the cost of 
raw material was mainly the explanation given by the economic agents. 
However, the findings regarding the interference in pricing decisions in 
the retail segment and other distortions of the market raise the question 
Essential and Orphan Drugs in Panama
Revista de Economía del Rosario. Vol. 23. No. 2. Julio-Diciembre 2020. 1-20
16
of whether other potential explanations are involved in this situation. Our 
findings also highlight the effectiveness of the current pricing policy based 
on competition with generic products and suggest a prompt review of the 
current trends in the market (Abdel Rida & Ibrahim, 2018; Degtiar, 2017).
Panama has a scarce national industry and is import-dependent, and thus, 
the conditions of competition are determined outside its borders. Moreover, 
the country is subject to price discrimination policies from the pharmaceutical 
industry, given that it is considered a medium-high income country (World 
Bank, 2017). Similarly, there has been little or no transfer of technology to 
developed countries, making it difficult for Panama to manufacture cost-
effective generic products. Controls given to the pharmaceutical companies 
of developed countries allow them to maintain control of investment in R&D 
in addition to determining prices under free trade agreements because large 
pharmaceutical companies seek to protect intellectual capital (Gamba, 2017; 
Lobo & Velásquez, 1997).
Currently, the benefits of free trade tend to be less extensive and limited 
to negotiating more specific items, such as the protection of property rights, 
ensuring the technological advantage for countries with highly developed 
pharmaceutical sectors (Van Norman & Eisenkot, 2017). Similarly, large mul-
tinational pharmaceutical firms establish different pricing strategies between 
countries and regions. Small and dependent countries that rely on imports, 
therefore, have few marketing mechanisms with regard to affordable prices, 
particularly for new products, such as those treating non-communicable 
diseases. The marketing of medicines based on the pharmaceutical industry 
strategies is complex and creates underlying inequalities at the social level 
and with access to drugs, which represents a challenge for the health sector 
in the face of important pricing policy.
Our study has strengths and limitations. Out-of-pocket surveys cannot 
be extrapolated to the national level; however, the results are similar to those 
of other studies in the context of social inequalities. Further, the scarcity of 
information collected regarding the handling of orphan drugs leaves us with 
only partial conclusions regarding the objective of this research.
To the best of our knowledge, this is the first comprehensive study in 
Panama that involves data from different sectors of the market of medicines. 
The findings provide a much broader picture of a slightly oligopolistic market 
structure that has been complemented by pricing mechanisms, and it also 
offers perceptions of the competition environment in terms of the prices 
of innovative and generic products in the three studied market segments.
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Conclusions
Our study shows that drug prices increased in an aligned manner in the 
marketing channel. Although it does not show the performance of a monopo-
listic practice, it does not make clear the independence of retail pharmacies to 
establish competitive prices. Similarly, the high percentage of people without 
social and private insurance and the increase in out-of-pocket expenses 
aggravates social inequality. This highlights the need to review the current 
pricing policy and consider other regulatory mechanisms.
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